168 related articles for article (PubMed ID: 37400844)
21. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience.
Espírito Santo V; Passos J; Nzwalo H; Carvalho I; Santos F; Martins C; Salgado L; Silva CE; Vinhais S; Vilares M; Salgado D; Nunes S
J Neurooncol; 2020 Apr; 147(2):459-463. PubMed ID: 32108293
[TBL] [Abstract][Full Text] [Related]
22. Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study.
Suenobu S; Terashima K; Akiyama M; Oguri T; Watanabe A; Sugeno M; Higashimori M; So K; Nishida Y
Neurooncol Adv; 2023; 5(1):vdad054. PubMed ID: 37287695
[TBL] [Abstract][Full Text] [Related]
23. Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer.
Zhang J; Wang X; Wang X; Hui A; Wu Z; Tian L; Xu C; Yang Y; Zhang W; Hu X
Invest New Drugs; 2021 Dec; 39(6):1549-1558. PubMed ID: 34109484
[TBL] [Abstract][Full Text] [Related]
24. A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.
Lin L; Pan H; Li X; Zhao C; Sun J; Hu X; Zhang Y; Wang M; Ren X; Luo X; Shan G; Hui AM; Wu Z; Liu H; Tian L; Shi Y
Lung Cancer; 2022 Apr; 166():98-106. PubMed ID: 35248866
[TBL] [Abstract][Full Text] [Related]
25. Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
Widemann BC; Dombi E; Gillespie A; Wolters PL; Belasco J; Goldman S; Korf BR; Solomon J; Martin S; Salzer W; Fox E; Patronas N; Kieran MW; Perentesis JP; Reddy A; Wright JJ; Kim A; Steinberg SM; Balis FM
Neuro Oncol; 2014 May; 16(5):707-18. PubMed ID: 24500418
[TBL] [Abstract][Full Text] [Related]
26. Safety and Efficacy of Mek Inhibitors in the Treatment of Plexiform Neurofibromas: A Retrospective Study.
Cacchione A; Fabozzi F; Carai A; Colafati GS; Baldo GD; Rossi S; Diana M; Megaro G; Milano GM; Macchiaiolo M; Crocoli A; De Ioris MA; Boccuto L; Secco DE; Zama M; Agolini E; Tomà P; Mastronuzzi A
Cancer Control; 2023; 30():10732748221144930. PubMed ID: 36598023
[TBL] [Abstract][Full Text] [Related]
27. Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity.
Gross AM; Glassberg B; Wolters PL; Dombi E; Baldwin A; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Whitcomb P; Paul SM; Steinberg SM; Venzon DJ; Martin S; Carbonell A; Heisey K; Therrien J; Kapustina O; Dufek A; Derdak J; Smith MA; Widemann BC
Neuro Oncol; 2022 Nov; 24(11):1978-1988. PubMed ID: 35467749
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Plexiform Neurofibromas with MEK Inhibitors: First Results with a New Therapeutic Option.
Vaassen P; Dürr NR; Rosenbaum T
Neuropediatrics; 2022 Feb; 53(1):52-60. PubMed ID: 34905788
[TBL] [Abstract][Full Text] [Related]
29. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.
Weiss B; Widemann BC; Wolters P; Dombi E; Vinks A; Cantor A; Perentesis J; Schorry E; Ullrich N; Gutmann DH; Tonsgard J; Viskochil D; Korf B; Packer RJ; Fisher MJ
Neuro Oncol; 2015 Apr; 17(4):596-603. PubMed ID: 25314964
[TBL] [Abstract][Full Text] [Related]
30. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.
Weiss B; Widemann BC; Wolters P; Dombi E; Vinks AA; Cantor A; Korf B; Perentesis J; Gutmann DH; Schorry E; Packer R; Fisher MJ
Pediatr Blood Cancer; 2014 Jun; 61(6):982-6. PubMed ID: 24851266
[TBL] [Abstract][Full Text] [Related]
31. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review.
Solares I; Viñal D; Morales-Conejo M; Rodriguez-Salas N; Feliu J
ESMO Open; 2021 Aug; 6(4):100223. PubMed ID: 34388689
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas.
Babovic-Vuksanovic D; Widemann BC; Dombi E; Gillespie A; Wolters PL; Toledo-Tamula MA; O'Neill BP; Fox E; MacDonald T; Beck H; Packer RJ
Pediatr Neurol; 2007 May; 36(5):293-300. PubMed ID: 17509460
[TBL] [Abstract][Full Text] [Related]
33. Management of neurofibromatosis type 1-associated plexiform neurofibromas.
Fisher MJ; Blakeley JO; Weiss BD; Dombi E; Ahlawat S; Akshintala S; Belzberg AJ; Bornhorst M; Bredella MA; Cai W; Ferner RE; Gross AM; Harris GJ; Listernick R; Ly I; Martin S; Mautner VF; Salamon JM; Salerno KE; Spinner RJ; Staedtke V; Ullrich NJ; Upadhyaya M; Wolters PL; Yohay K; Widemann BC
Neuro Oncol; 2022 Nov; 24(11):1827-1844. PubMed ID: 35657359
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, in adult patients with advanced melanoma and neurofibromatosis type 1 (NF1) and model informed dosing recommendations for NF1 pediatrics.
Tan Y; Cui A; Qian L; Li C; Wu Z; Yang Y; Han P; Huang X; Diao L
Front Pharmacol; 2023; 14():1101991. PubMed ID: 36755948
[No Abstract] [Full Text] [Related]
35. Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas.
Jakacki RI; Dombi E; Steinberg SM; Goldman S; Kieran MW; Ullrich NJ; Pollack IF; Goodwin A; Manley PE; Fangusaro J; Allen R; Widemann BC
Neuro Oncol; 2017 Feb; 19(2):289-297. PubMed ID: 27510726
[TBL] [Abstract][Full Text] [Related]
36. Plexiform neurofibromas in NF1: toward biologic-based therapy.
Packer RJ; Gutmann DH; Rubenstein A; Viskochil D; Zimmerman RA; Vezina G; Small J; Korf B
Neurology; 2002 May; 58(10):1461-70. PubMed ID: 12041525
[TBL] [Abstract][Full Text] [Related]
37. Selumetinib in the Treatment of Symptomatic Intractable Plexiform Neurofibromas in Neurofibromatosis Type 1: A Prospective Case Series with Emphasis on Side Effects.
Baldo F; Grasso AG; Cortellazzo Wiel L; Maestro A; Trojniak MP; Murru FM; Basso L; Magnolato A; Bruno I; Barbi E
Paediatr Drugs; 2020 Aug; 22(4):417-423. PubMed ID: 32533336
[TBL] [Abstract][Full Text] [Related]
38. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
39. Concomitant variants in NF1, LZTR1 and GNAZ genes probably contribute to the aggressiveness of plexiform neurofibroma and warrant treatment with MEK inhibitor.
Cohen-Barak E; Toledano-Alhadef H; Danial-Farran N; Livneh I; Mwassi B; Hriesh M; Zagairy F; Gafni-Amsalem C; Bashir H; Khayat M; Warrour N; Sher O; Marom D; Postovsky S; Dujovny T; Ziv M; Shalev SA
Exp Dermatol; 2022 May; 31(5):775-780. PubMed ID: 34913528
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety profile of selumetinib in symptomatic inoperable plexiform neurofibromas.
Sharawat IK; Panda PK; Sihag RK; Panda P; Dawman L
J Neurosurg Sci; 2022 Dec; 66(6):501-510. PubMed ID: 35301838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
